Transcript Drug Delivery Technology Options

Biophan Technologies, Inc.
Company Overview
Michael Weiner, CEO
“Nanotechnology: The Future is Now” Symposium
July 29, 2005
Biophan’s Mission
• Provide competitive advantage through innovation to
biomedical device and pharmaceutical companies
• Benefiting patient care, our customer’s marketshare,
and Biophan shareholders
CAUTION! CAUTION!
• FORWARD LOOKING STATEMENTS
FOLLOW
• FORWARD LOOKING STATEMENTS
FOLLOW
Strategy & Tactics
• Enable over $12 billion worth of medical devices shipping annually
safe for use with MRI, and imageable. Many are not:
– Guidewires, catheters, endoscopes, biopsy needles
– Pacemakers, defibrillators, neurostimulators, drug pumps (safety
issues, also imaging issues), pain control devices
– Stents, embolism clips, aneurysm clips, artificial hips, knees, most
other orthopedics
• Create or Acquire Other Innovations
Business Model
• Offering our customers competitive advantage
– Through proprietary solutions that can gain marketshare for them
– FDA approval is pursued by the customer
– Marketing and distribution of the final device is their responsibility
• We sell high margin components and develop annuities for our
shareholders
Biophan’s Solutions
• MRI Safety: (many products contraindicated)
– RF filter from Johns Hopkins (heating)
– “Anti-Antenna” lead design (heating & induced voltages)
– MRI Safe non-magnetic motor
• MRI Visualization:
– Resonant Circuits
– Nanomagnetic Particle Coatings
– Thick and thin film coatings
• Longer Lasting Batteries, powered by body heat
Patent Protection
• 213 Patents Pending or Issued
– 156 U.S. Patents
• 50 issued
• 106 pending or allowed
– 57 International Pending or Issued
• Owned by Biophan or licensed exclusively to Biophan for
the medical market
Figures as of May 24, 2006
Relationship With Boston Scientific
• Definitive agreements signed for equity investment and
technology license
• $5.75 million investment will be made by August 15, 2005
• Royalty rates of 3-5%
MRI Device Imaging
1
2
3
Biophan’s thin-film
nanomagnetic particle
coating technology
provides a controllable,
“magnetic” signal
capable of creating an
image of the coated
device.
#3 is uncoated.
SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.
1.5 Tesla MRI Artifacts of Current Stents
Cobalt
Expanded
Stents
Original size
316L stainless
steel
Crimped
Stents
With existing
stent
technology, no
useful images
can be
obtained from
within common
stents using
MRI.
Imaging of In-Stent Blood Clots
Using Biophan Resonator Technology
Resonant Stent
Blood Clot
Cross
Sectional
Schematic of
Stent with
blood clot
Video
Biophan’s technology enables imaging of
1 Tesla Philips NT, head coil, TR=300ms,
the blood clot within the stent
TE=6ms, FA=40°, transversal
Biothermal Battery
• Goal: To provide a long-lived electrical power system for
implanted medical devices
– Powered by body heat differential.
• Batteries are a $500 million market, sell for $100 to $225
each in the pacemaker, defibrillator and drug pump
markets
• Sold to same customers who need MRI safety
• Nanomaterials brings this capability within striking
distance. We hold issued and pending patents
Agreement with NASA
• Announced on August 17th a deal with NASA Ames Research
Center for Nanotechnology to jointly develop the biothermal
battery
– NASA wants technology for their long duration manned MARS
mission for biosensing and miniature therapeutic devices
– Biophan gets commercial rights to jointly developed and NASA
developed technology
– Nanotechnology and materials science advances makes the
biothermal battery possible
• Non-Magnetic
• MRI-Safe and
Imageable
• Greater efficiency
• Enables precision
20 nm movements
• Ideal for drug
pumps, cryogenic
applications,
implantables
• Biophan holds
worldwide medical
distribution rights, +
equity
Controlled
Magnetic Field B
Controlled
Magnetic Field
Controlled
Magnetic Field A
Surface Elution on Demand
Particle type A
Drug A
Particle type B
Drug B
Polymer Coating
Nanomagnetic layer
Substrate
Drug bound to
NMP carrier
Reloading Drug Eluting Coatings
Drug bound to
NMP carrier
Controlled
Magnetic Field
Concentration Gradient
Drug
Molecules
Polymer Coating
Nanomagnetic layer
Substrate
Guided Drug Delivery
Solid tumor
Apply magnetic
field to concentrate
particles
Modulate field to
release drug from
particles
Other options for targeting:
1 - Direct injection into
tumor site
2 - Coating NMP with
antibodies to target tumor
Inject NMPs IV,
NMP will circulate
through the blood stream
Markets
•
•
•
•
•
•
•
Medical devices (safe &/or image): $12 billion
Battery: $500 million
Contrast Agents: $800 million
Drug Pumps: $1 billion
Drug Delivery: $40 billion
We would like to achieve a slice of each.
Once a deal is underway, patents and annuity streams can last a long
time;
• We anticipate money on signing, through development; plus
milestones, royalties, high margin components
Management
• Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with
a 400 person organization
• Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the
same J&J division
• John Lanzafame, President, Nanolution Division – former
President STS Biopolymers, acquired by Angiotech (ANPI)
• Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA
in public and private firms
• Michael Friebe, Ph.D.
• Andreas Melzer, MD
Biophan (OTC: BIPH)
We don’t make medical devices;
We make them safe, and imageable, for MRI
And other competitive advantages for our customers
Four of our six technologies are based on nanotechnology
WWW.BIOPHAN.COM